SCHEMBL25525537

SCHEMBL25525537

CC[C@@H]1CCCN1c1nc(Nc2cn(-c3cc(OC)c(OC)c(OC)c3)cn2)c2c(ccn2S(=O)(=O)c2ccc(C)cc2)n1

nearest known ligand 0.79

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ACVR1 Q04771 20/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20589510 0.94 ACVR1 (0.80) ACVR1
SCHEMBL20589515 0.94 ACVR1 (0.80) ACVR1
SCHEMBL25199061 0.88 ACVR1 (1.00) ACVR1
SCHEMBL25266220 0.88 ACVR1 (1.00) ACVR1
SCHEMBL25525608 0.88 ACVR1 (0.80) ACVR1
SCHEMBL25512089 0.84 ACVR1 (0.65) ACVR1
SCHEMBL20588640 0.83 ACVR1 (0.77) ACVR1
SCHEMBL31095352 0.83 ACVR1 (0.77) ACVR1
SCHEMBL20588643 0.83 ACVR1 (0.77) ACVR1
SCHEMBL30548857 0.83 ACVR1 (0.77) ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661426-B2 Imidazole-containing inhibitors of ALK2 kinase BIOCRYST PHARMACEUTICALS, INC. (US) 2023-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11661426-B2 Imidazole-containing inhibitors of ALK2 kinase ALK, ACVR2B, ACVR2A ACVR1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.